Ranbaxy wins patent case in US
Ranbaxy Laboratories said a US court found its generic version of GlaxoSmithkline's antibiotic Ceftin did not infringe Glaxo
Ranbaxy Laboratories said a US court found its generic version of GlaxoSmithkline's antibiotic Ceftin did not infringe Glaxo